Could Biohaven Pharmaceutical Holding Company LTD. Commo (NYSE:BHVN) See a Reversal After Less Sellers Came In?

May 17, 2018 - By Harriett Tippett

The stock of Biohaven Pharmaceutical Holding Company LTD. Commo (NYSE:BHVN) registered a decrease of 11.35% in short interest. BHVN’s total short interest was 2.79M shares in May as published by FINRA. Its down 11.35% from 3.14M shares, reported previously. With 362,800 shares average volume, it will take short sellers 8 days to cover their BHVN’s short positions. The short interest to Biohaven Pharmaceutical Holding Company LTD. Commo’s float is 16.91%.

The stock increased 1.14% or $0.34 during the last trading session, reaching $30.29. About 312,152 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $1.17 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

More notable recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Seekingalpha.com which released: “Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant” on April 23, 2018, also Prnewswire.com with their article: “Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients …” published on May 09, 2018, Streetinsider.com published: “Biohaven (BHVN) to Present Additional Phase 3 Rimegepant Data at AAN 2018 on April 22nd” on April 19, 2018. More interesting news about Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) were released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon …” published on April 19, 2018 as well as Prnewswire.com‘s news article titled: “Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results” with publication date: May 15, 2018.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: